RGNCY-0064 (NASTRp (CREB)-CREB CBP inhibitor)
SOLD OUT!! E-mail us at info@reagency.co if you are interested in this product.
NASTRp (Ntpthol AS-TR phosphate) is an inhibitor of cyclic-AMP responsive element-binding protein (CREB)-CREB binding protein (CBP) transcription factor complex. NASTRp is a potential therapeutic agent for lung adenocarcinoma. NASTRp was shown to inhibit oncogenic cell properties through cell cycle arrest with concomitant suppression of tumor-promoting autophagy with down-regulation of of Atg5-12 and Atg7 and accumulation of p62 in human lung cancer cell lines. Furthermore, NASTRp was also shown to induce expression of endoplasmic reticulum stress marker,s DDIT3/CHOP and led to apoptosis along with BIM induction. NASTRp targeting the CREB-CBP transcription complex is a novel and potent anti-cancer agent showing multiple effects on critical pathways in cell biology. This represents a novel class of targeted therapies in cancer.
Systematic Name: 3-((4-chloro-2-methylphenyl)carbamoyl)naphthalen-2-yl dihydrogen phosphate
SMILES: OP(OC1=CC2=CC=CC=C2C=C1C(NC3=C(C)C=C(Cl)C=C3)=O)(O)=O
Formula: C18H15ClNO5P
Mol Wt: 391.74
PMID: 25897662
Tags: Cancer, autophagy, small molecule, Tumor, NASTRp, RGNCY-0064, CREB, CBP, CREB binding protein, lung, adenocarcinoma, Atg, p62, DDIT3, CHOP